Statement: Patients with E2 outside the premenopausal range are ineligible for the primary trial.
Primary_evidence: INCLUSION CRITERIA   Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive   Premenopausal, defined as any of:   Last menstrual period within 3 months, or   Post-hysterectomy without bilateral oophorectomy and with follicle-stimulating hormone (FSH) in the premenopausal range, or,   If tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range   Either positive estrogen and/or progesterone receptor determination by Immunohistochemistry (IHC) or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen.   Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2   Granulocytes > 1500/mm^3   Platelets > 100,000/mm^3   Serum glutamic oxaloacetic transaminase (SGOT) < 2.5 x upper limit of normal   Total bilirubin < 1.5 mg/dL   May have received irradiation to bony sites of disease for pain control or for prevention of fracture. The irradiated site(s) will NOT be evaluable for disease response.   Must be using effective contraception or not be of childbearing potential   Signed written informed consent   INCLUSION CRITERIA   Active, unresolved infection   Active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years   Prior treatment with an aromatase inhibitor or inactivator   Prior treatment with an luteinizing hormone-releasing hormone (LH/RH) agonist/antagonist   Adjuvant chemotherapy within 6 months of study entry.   Received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment   Central nervous system metastasis   Lymphangitic pulmonary metastasis   Pregnant or lactating